Observational Study for the Evaluation of Immune-mediated Endocrinological Adverse Events in Patients With Hematological Malignancies and Subjected to Treatment With Immune-checkpoint Inhibitors
Recruiting
Observational Study
Hematological Malignancies
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 100 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Retrospective / prospective observational study of endocrinological adverse events in hematologic patients treated with immunological checkpoint inhibitors
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Retrospective cohort
* patients aged\> 18 years
* cyto-histological diagnosis of mature lymphoproliferative syndrome of B or T lymphocyte origin
* advanced stage of illness (relapsed or refractory)
* patients undergoing treatment with immune anticheckpoint antibodies.
* written…
Contacts